Oura Health has confidentially filed for a US Initial Public Offering, with plans to launch as early as September 2026 at a valuation exceeding $16 billion. The firm aims to raise up to $3 billion in this listing. While the company is not traded on Indian exchanges, its entry into public markets marks a key development in the competitive wearable technology sector.
Oura Health, the manufacturer of the popular sleep-tracking smart ring, is preparing to enter the public markets. The company confidentially filed for a U.S. Initial Public Offering (IPO) in May 2026 and is currently targeting a September 2026 launch. The offering seeks to secure a valuation of more than $16 billion, with the company aiming to raise up to $3 billion from the exercise. It is important for investors to note that Oura Health remains a private company and its shares are not currently available for trading on Indian stock exchanges like the NSE or BSE.
The upcoming listing comes as Oura looks to capitalize on the rapid growth of the global wearables market. The company has focused on expanding its business from a niche provider of health tracking for tech-savvy users to a broader brand centered on sleep, stress, and recovery. According to recent reports, the firm is aiming to reach between $1.5 billion and $2 billion in revenue by 2026, building on revenue that reportedly exceeded $500 million in 2024.
While the company has seen strong growth, the path to a public listing is not without challenges. The wearable technology sector has become increasingly crowded. Major technology giants, including Samsung with its Galaxy Ring, have entered the space, creating intense competition for market share. These large competitors often have deeper pockets and wider distribution networks, which can pressure smaller, specialized firms.
Investors are also closely watching the company’s regulatory and legal standing. Oura has faced legal challenges regarding the accuracy of its sleep-tracking and health-monitoring features. Critics and some legal filings have questioned whether the device provides clinical-grade data, a claim that remains a point of contention. Should these regulatory concerns persist, they could impact the company's brand reputation or result in additional costs.
Market conditions will also play a critical role in the success of the IPO. The final valuation and the timing of the share sale will depend on broader economic factors, including investor appetite for new technology stocks and overall market volatility. The underwriting syndicate for this potential IPO is expected to include major financial institutions such as Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Co., and Jefferies.
For those tracking the broader wellness and wearables sector, the next steps include the release of updated financial disclosures, regulatory approvals for the IPO process, and the company’s ability to defend its market position against newer entrants. Investors will also look for management's strategy to sustain growth in a post-pandemic environment where consumer spending on gadgets is under constant scrutiny.